Ocular manifestations in Congenital Zika syndrome: About a case of torpedo maculopathy.
Congenital zika syndrome
Spectral-domain optical coherence tomography
Torpedo maculopathy
Zika virus
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
15
10
2019
revised:
23
01
2020
accepted:
21
02
2020
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
To describe pertinent imaging studies and clinical features of a torpedo maculopathy presumably associated with congenital Zika syndrome. A 23-month-old child, with no prematurity or microcephaly at birth, was examined in the Ophthalmology department of the University Hospital of Fort-de-France (Martinique, French West Indies), as part of a systematic screening of malformations in children suspected of maternal-fetal exposure to Zika virus. Zika infection was confirmed in the mother's serum by Reverse Transcriptase Polymerase Chain Reaction during the third trimester of pregnancy. Fundus examination found a unilateral hypopigmented retinal lesion, temporal to the macula, with an apex pointing to the fovea. Explorations in spectral-domain optical coherence tomography showed a subretinal cleft with broadening and attenuation of the interdigitation zone, elevation of the outer limiting membrane and the ellipsoid zone, without thinning of the outer retinal layers. There is a proven risk of congenital eye defects after Zika infection during pregnancy. We report here the first case of torpedo maculopathy without microcephaly, in a child suspected of maternal-fetal exposure to Zika.
Identifiants
pubmed: 32140614
doi: 10.1016/j.ajoc.2020.100626
pii: S2451-9936(20)30022-0
pii: 100626
pmc: PMC7052067
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100626Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The following authors have no financial disclosures.
Références
Lancet Infect Dis. 2016 Jun;16(6):653-660
pubmed: 26897108
Arch Ophthalmol. 2010 Apr;128(4):499-501
pubmed: 20385950
Eye (Lond). 2018 Aug;32(8):1315-1320
pubmed: 29556011
Curr Opin Ophthalmol. 2017 Nov;28(6):595-599
pubmed: 28795959
Emerg Infect Dis. 2008 Aug;14(8):1232-9
pubmed: 18680646
JAMA Ophthalmol. 2016 May 1;134(5):529-535
pubmed: 26865554
Arch Ophthalmol. 1992 Oct;110(10):1358-9
pubmed: 1417528
Lancet. 2016 Jun 18;387(10037):2502
pubmed: 27287830
Optom Vis Sci. 2003 Aug;80(8):556-63
pubmed: 12917574
Euro Surveill. 2014 Apr 03;19(13):
pubmed: 24721538
J Am Optom Assoc. 1997 Jun;68(6):373-6
pubmed: 9190137
JAMA Ophthalmol. 2017 May 1;135(5):440-445
pubmed: 28418539
Ophthalmology. 2016 Aug;123(8):1788-1794
pubmed: 27236271
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
Clin Exp Ophthalmol. 2015 May-Jun;43(4):342-8
pubmed: 25266677